SCHEMBL3011255

SCHEMBL3011255

O=S(=O)(c1cc(Cl)ccc1Cl)C1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 2/20 0.37
GAA P10253 1/20 0.37
AR P10275 2/20 0.37
ALDH1A1 P00352 2/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
RECQL P46063 1/20 0.35
CNR1 P21554 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
USP2 O75604 1/20 0.34
KMT2A Q03164 2/20 0.34
ATM Q13315 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012479 0.94 MAPT (0.39) MAPTL3MBTL1LMNAGAAAR
SCHEMBL3003801 0.94 GAA (0.36) MAPTL3MBTL1LMNAGAAAR
SCHEMBL3008156 0.93 GAA (0.39) MAPTL3MBTL1LMNAGAAAR
SCHEMBL3006085 0.92 GAA (0.38) MAPTL3MBTL1LMNAGAAAR
SCHEMBL3019044 0.92 CACNA1G (0.36) MAPTL3MBTL1GAAARALDH1A1
SCHEMBL3009884 0.92 MAPT (0.36) MAPTL3MBTL1GAAARALDH1A1
SCHEMBL3013157 0.91 MAPT (0.36) MAPTL3MBTL1LMNAGAAALDH1A1
SCHEMBL3011591 0.91 ACHE (0.36) MAPTL3MBTL1LMNAGAAALDH1A1
SCHEMBL3021640 0.91 ACHE (0.36) MAPTL3MBTL1LMNAGAAALDH1A1
SCHEMBL3009939 0.90 CTSS (0.42) MAPTL3MBTL1LMNAARALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885L3MBTL1 1847/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.